A Virtual Reality View: Long-Term Management of Atopic Dermatitis: New and Emerging Targeted Systemic Therapies

 

This program is not sponsored or programmed by the AAAAI

 
Sunday, February 24, 2019
7:00 AM – 8:00 AM

Location

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Meeting room: Yerba Buena Salon 7

 

REGISTER NOW!
Already Registered?
SIGN IN

 
 

WEBCAST DATE

SUNday, February 24, 2019

10:00 AM Eastern    9:00 AM Central    8:00 AM Mountain    7:00 AM Pacific

Add to Calendar 02/24/2019 10:00 AM 02/24/2019 11:00 AM America/New_York A Virtual Reality View: Long-term Management of Atopic Dermatitis: New and Emerging Targeted Systemic Therapies A Virtual Reality View: Long-term Management of Atopic Dermatitis: New and Emerging Targeted Systemic Therapies Live Simulcast Med Learning Group info@medlearninggroup.com false MM/DD/YYYY atZOdzeAgzXtBkKLjmOo27579

 

PROGRAM FEATURES

    • Interactive, case-based learning environment

PROGRAM DESCRIPTION

While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This program will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.

FACULTY

Joy Wan, MD, MSCE
Department of Dermatology
University of Pennsylvania
Philadelphia, PA

AGENDA

I. AD in pediatric patients: An overview
    a. Epidemiology and burden
    b. Pathophysiology
    c. Comorbid conditions

II. Challenges in the diagnosis and Long-term management of AD in pediatric patients
    a. Diagnosis made based on clinical signs and symptoms only
    b. Clinical phenotypes and endophenotypes show a wide range of heterogeneity in age of onset, course, and presentation
    c. Utility of available diagnostic tools to assess disease, severity, and outcomes
    d. Utility of biomarkers for diagnosis, treatment decision-making, and treatment response
    e. Inconsistent management patterns
    f. Selection of optimal front-line therapy for each patient based on traditional standard of care treatment approaches and types of treatment regimens
    g. Non-adherence as a barrier to effective management
    h. Effect of management decisions on patient QoL

III. Newly-approved and Emerging Targeted Therapeutic Agents for the Management of AD in Pediatric Patients
    a. Topical agents
    b. Biologics
    c. Small molecules

IV. Case Study

V. Conclusions and Q & A

LEARNING OBJECTIVES

After completing the educational activity, learners should be better able to:

  • Review recent pathophysiological findings in AD that have informed the selection of new therapeutic targets
  • Describe best practices for severity assessment and diagnosis of moderate-to-severe AD in pediatric patients, accounting for biomarkers, phenotype/genotype, comorbidities, and disease burden
  • Explain the mechanisms of action and clinical profiles of new and emerging targeted systemic agents for the long-term treatment of AD in pediatric patients
  • Discuss how different biomarkers, comorbidities and adherence barriers play a role in long-term treatment decision making for pediatric patients with AD

TARGET AUDIENCE

This activity is intended for US-based dermatologists and other health care professionals who diagnose, treat, and/or manage patients with AD.

DISCLAIMER

Med Learning Group makes every effort to develop educational activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

 

WEBCAST REGISTRATION

Please use the following form to register for this webcast. You will receive an email confirmation shortly after you complete the registration.

If you are unable to register online or do not receive your confirmation email after registering, please email us at support@performedia.com.

Registration Form


*Required field

WEBCAST SIGNIN

Please enter your registered email and click the Sign In button to watch the Live Simulcast.

If you are unable to sign in or watch the live simulcast, please email us at support@performedia.com.

 

 

 

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.